BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36114130)

  • 21. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
    Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
    Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
    PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
    Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM
    J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
    Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH
    Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
    Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
    PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
    Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
    Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with a HSV-2 UL24 mutant induces a protective immune response in murine and guinea pig vaginal infection models.
    Visalli RJ; Natuk RJ; Kowalski J; Guo M; Blakeney S; Gangolli S; Cooper D
    Vaccine; 2014 Mar; 32(12):1398-406. PubMed ID: 24462481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.
    Awasthi S; Onishi M; Lubinski JM; Fowler BT; Naughton AM; Hook LM; Egan KP; Hagiwara M; Shirai S; Sakai A; Nakagawa T; Goto K; Yoshida O; Stephens AJ; Choi G; Cohen GH; Katayama K; Friedman HM
    Viruses; 2023 May; 15(5):. PubMed ID: 37243234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
    Brans R; Yao F
    BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
    Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER
    Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
    Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
    Iyer AV; Pahar B; Chouljenko VN; Walker JD; Stanfield B; Kousoulas KG
    Virol J; 2013 Oct; 10():317. PubMed ID: 24165088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Adenovirus-Based Recombinant Herpes Simplex Virus 2 (HSV-2) Therapeutic Vaccine Is Highly Protective against Acute and Recurrent HSV-2 Disease in a Guinea Pig Model.
    Wan M; Yang X; Sun J; Ding X; Chen Z; Su W; Cai L; Hou A; Sun B; Gao F; Jiang C; Zhou Y
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
    Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
    PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies.
    Stanfield BA; Pahar B; Chouljenko VN; Veazey R; Kousoulas KG
    Vaccine; 2017 Jan; 35(4):536-543. PubMed ID: 28017425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.